GT-008 / Pentixapharm - LARVOL DELTA

Targeting tumor-specific glycosylation patterns on proteins for radiotheranostics: Preclinical studies with different antibody formats of GT-008, a novel anti-CD24 mAb for selective delivery of radioisotopes (SNMMI 2026) - "This systematic comparison highlights the importance and versatility of antibody engineering, which is crucial for the development of safe and effective antibody-based radioligands. The findings will further guide the selection of a suitable antibody format for further nonclinical and first-in-human studies during development of GT-008 as a theranostic radioligand for solid tumors, e.g. female cancers."

First-in-human • Preclinical • Breast Cancer • Oncology • Solid Tumor • CD24

Targeting tumor-specific glycosylation patterns on proteins for radiotheranostics: Preclinical studies with different antibody formats of GT-008, a novel anti-CD24 mAb for selective delivery of radioisotopes (SNMMI 2026) - "This systematic comparison highlights the importance and versatility of antibody engineering, which is crucial for the development of safe and effective antibody-based radioligands. The findings will further guide the selection of a suitable antibody format for further nonclinical and first-in-human studies during development of GT-008 as a theranostic radioligand for solid tumors, e.g. female cancers."

First-in-human • Preclinical • Breast Cancer • Oncology • Solid Tumor • CD24

GT-008: A monoclonal antibody enabling selective radionuclide delivery to a tumor-associated glycosylation form of CD24 - Preclinical proof-of-concept study (AACR 2026) - "All treatments were well tolerated. These findings supports the development of GT-008 as a theranostic radioligand for solid tumors, including female cancers, while supporting its broader potential across CD24-directed modalities such as ADCs, bispecifics, and cellular CAR therapies."

Preclinical • Breast Cancer • Oncology • Solid Tumor • CD24

Improving druggability of a promising tumor target by the novel glycosylation-dependent mAb GT-008 for treatment of solid tumors (AACR 2025) - "With its improved therapeutic window due to the strong differentiation between healthy and tumor tissue, GT-008 is exceptionally suitable for different therapeutic modalities, such as drug delivery (ADC, RIT) or cellular therapies (CARs). An in vitro and in vivo proof-of-concept study as therapeutic radioimmunoconjugate has been initiated."

IO biomarker • Oncology • Solid Tumor • CD24